E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Cardiac papillary fibroelastoma and stroke. Echocardiographic diagnosis and guide to excision.
TL;DR: A young male patient who had a stroke due to a mitral valve papillary fibroelastoma is described, and not only did preoperative echocardiography establish the diagnosis, but intraoperative transesophageal two-dimensional echOCardiography was utilized to guide tumor excision.
Journal ArticleDOI
Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: Lessons from 4 international fibrinolytic therapy trials
David Hasdai,Eric J. Topol,Rakhi Kilaru,Alexander Battler,Robert A. Harrington,A Vahanian,E. Magnus Ohman,Christopher B. Granger,Frans Van de Werf,Maarten L. Simoons,Christopher M. O'Connor,David R. Holmes +11 more
TL;DR: In this article, the authors examined the incidence, timing, and consequences of mild-to-moderate heart failure complicating acute myocardial infarction (MI) and its impact on short-term outcomes.
Journal ArticleDOI
Transcription factor MEF2A mutations in patients with coronary artery disease
M. R Krishna Bhagavatula,Chun Fan,Gong Qing Shen,June Cassano,Edward F. Plow,Eric J. Topol,Qing Kenneth Wang +6 more
TL;DR: It is suggested that CAD/MI can result from a spectrum of MEF2A transcription dysfunctions ranging from loss-of-function to dominant-negative suppression and that a significant percent of the CAD/ MI population may carry mutations in MEF 2A, although further definition of the prevalence is warranted.
Journal ArticleDOI
Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction.
Albert W. Chan,Derek P. Chew,Deepak L. Bhatt,David J. Moliterno,Eric J. Topol,Stephen G. Ellis +5 more
TL;DR: Treatment with the combination of stent and abciximab resulted in higher procedural Thrombolysis In Myocardial Infarction 3 flow rates and a long-term mortality benefit in patients with cardiogenic shock complicating acute myocardial infarction.
Journal ArticleDOI
Protective alleles and modifier variants in human health and disease
TL;DR: By delineating the genomic factors that are protective against disease, there is potential to derive highly effective, genomically anchored medicines that assist in maintaining health.